|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intracellular Signals of T Cell Costimulation显示文摘Ligation of T cell receptor (TCR) alone is insufficient to induce full activation of T lymphocytes. Additional ligand-receptor interactions (costimulation) on antigen presenting cells (APCs) and T cells are required. T cell costimulation has been shown to be essential for eliciting efficient T cell responses,involving all phases during T cell development. However,the mechanisms by which costimulation affects the function of T cells still need to be elucidated. In recent years,advances have been made in studies of costimulation as potential therapies in cancer,infectious disease as well as autoimmune disease. In this review,we discussed intracellular costimulation signals that regulate T cell proliferation,cell cycle progression,cytokine production,survival,and memory development. In general,the pathway of phosphoinositide-3 kinase (PI3K)/protein kinase B (PKB,also known as Akt)/nuclear factor κB (NF-κB) might be central to many costimulatory effects. Through these pathways,costimulation controls T-cell expansion and proliferation by maintenance of survivin and aurora B expression,and sustains long-term T-cell survival and memory development by regulating the expression of bcl-2 family members. | Fengyang Tylan Lei Rizwanul Haque | 2008 | Cellular & Molecular Immunology2008，5，4： | 7 |
| 2 | Insulin-Degrading Enzyme: A Link Between Alzheimerμs and Type 2 Diabetes Mellitus显示文摘 | Rizwanul Haque Aamir Nazir | 2014 | CNS & Neurological Disorders - Drug Targets2014，，2： | 1 |
| 3 | T lineage differentiation from induced pluripotent stem cells显示文摘 | Fengyang Lei Rizwanul Haque Lauren Weiler Kent E. Vrana Jianxun Song | 2009 | Cellular Immunology2009，，1： | 1 |
| 4 | The Regulation of FoxP3-Expressing Regulatory T Cells显示文摘 | Rizwanul Haque Fengyang Lei Xiaofang Xiong Jianxun Song | 2011 | Endocrine, Metabolic and Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine and Metabolic Disorders)2011，，4： | 1 |
| 5 | Mesenchymal stem cell-derived exosomes:Shaping the next era of stroke treatment显示文摘Exosome-based treatments are gaining traction as a viable approach to addressing the various issues faced by an ischemic stroke.These extracellular vesicles,mainly produced by mesenchymal stem cells,exhibit many properties with substantial therapeutic potential.Exosomes are particularly appealing for stroke therapy because of their low immunogenicity,effective cargo transport,and ability to cross the blood–brain barrier.Their diverse effects include neuroprotection,angiogenesis stimulation,inflammatory response modulation,and cell death pathway attenuation,synergistically promoting neuronal survival,tissue regeneration,and functional recovery.Exosomes also show potential as diagnostic indicators for early stroke identification and customized treatment options.Despite these promising qualities,current exosome-based therapeutics have some limitations.The heterogeneity of exosome release among cell types,difficulty in standardization and isolation techniques,and complications linked to dosage and targeted administration necessitates extensive investigation.It is critical to thoroughly understand exosomal processes and their complicated interactions within the cellular milieu.To improve the practicality and efficacy of exosome-based medicines,research efforts must focus on improving production processes,developing robust evaluation criteria,and developing large-scale isolation techniques.Altogether,exosomes’multifunctional properties offer a new route for transforming stroke treatment and significantly improving patient outcomes. | Arshi Waseem Saudamini Rizwanul Haque Miroslaw Janowski Syed S.Raza | 2023 | Neuroprotection2023，1，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员